Novartis Ag Stock Price To Earnings To Growth
| NOVN Stock | CHF 98.29 1.01 1.04% |
Novartis AG fundamentals help investors to digest information that contributes to Novartis' financial success or failures. It also enables traders to predict the movement of Novartis Stock. The fundamental analysis module provides a way to measure Novartis' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novartis stock.
Novartis |
Novartis AG Company Price To Earnings To Growth Analysis
Novartis' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Current Novartis Price To Earnings To Growth | 5.74 X |
Most of Novartis' fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novartis AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, Novartis AG has a Price To Earnings To Growth of 5.7375 times. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The price to earnings to growth for all Switzerland stocks is 17.33% lower than that of the firm.
Novartis Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novartis' direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novartis could also be used in its relative valuation, which is a method of valuing Novartis by comparing valuation metrics of similar companies.Novartis is currently under evaluation in price to earnings to growth category among its peers.
Novartis Fundamentals
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0645 | |||
| Profit Margin | 0.13 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 194.1 B | |||
| Shares Outstanding | 2.12 B | |||
| Shares Owned By Insiders | 3.74 % | |||
| Shares Owned By Institutions | 33.74 % | |||
| Price To Earning | 25.40 X | |||
| Price To Book | 3.25 X | |||
| Price To Sales | 3.48 X | |||
| Revenue | 51.83 B | |||
| Gross Profit | 36.74 B | |||
| EBITDA | 16.39 B | |||
| Net Income | 6.96 B | |||
| Cash And Equivalents | 4.64 B | |||
| Cash Per Share | 9.00 X | |||
| Total Debt | 21.78 B | |||
| Debt To Equity | 0.49 % | |||
| Current Ratio | 1.38 X | |||
| Book Value Per Share | 28.00 X | |||
| Cash Flow From Operations | 14.24 B | |||
| Earnings Per Share | 2.92 X | |||
| Price To Earnings To Growth | 5.74 X | |||
| Target Price | 86.92 | |||
| Number Of Employees | 102 K | |||
| Beta | 0.47 | |||
| Market Capitalization | 170.42 B | |||
| Total Asset | 117.45 B | |||
| Z Score | 4.2 | |||
| Annual Yield | 0.04 % | |||
| Five Year Return | 3.52 % | |||
| Net Asset | 117.45 B | |||
| Last Dividend Paid | 3.46 |
About Novartis Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novartis AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novartis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novartis AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Novartis Stock Analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.